LL-37 (Cathelicidin) vs TB-500

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

TB-500

Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.

Full details →

Side-by-Side Comparison

Aspect	LL-37 (Cathelicidin)	TB-500
Dose Range	500 mcg–1.6 mg	2 mg–2.5 mg
Frequency	1x daily	Less than daily
Cycle Length	2–4 weeks	4–8 weeks
Route	topical	subcutaneous
Mechanism	Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.	TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing.
Typical Dosage	Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.	Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks.
Administration	Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.	Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites.
Side Effects	Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.	May cause temporary fatigue, headache, or localized irritation at injection sites.
Best For	Recovery & Healing	Muscle Growth Recovery & Healing